HOME >> MEDICINE >> NEWS
American Heart Association Comment On New England Journal Of Medicine Report OnCalcium Antagonist Nisoldipine (March 5 issue)

revention and progression of diabetes in equal number of individuals. A secondary goal of the study was to determine if the drugs could prevent cardiovascular disease, a leading cause of death among individuals with diabetes.

The study found that nisoldipine (Sular) was linked with a higher rate of fatal and non-fatal heart attacks -- a total of 25 compared to five for enalapril in this particular group. Despite these striking differences, the authors of the study stress that "it is plausible that the findings resulted from a protective effect of enalapril and not a deleterious effect of nisoldipine."

Other calcium antagonists include: nimodipine (Nimotop); verapamil (Calen, Isoptin, Verelan); nicardipine (Cardene); diltiazem (Cardizem, Dilacor); isradipine (DynaCirc); amlodipine (Norvasc); felodipine (Plendil); nifedipine (Procardia); and bepridil (Vascor).


'"/>

Contact: Carole Bullock
caroleb@amhrt.org
214-705-1279
American Heart Association
3-Mar-1998


Page: 1 2

Related medicine news :

1. Consumers with disabilities empowered by American Disabilities Act
2. Definition of persistent vegetative state available from American Academy of Neurology
3. African-American women with endometrial cancer have more aggressive cancer than Caucasian women
4. New colorectal cancer screening recommendations for African Americans
5. American Thoracic Society Journal news tips for March 2005 (second issue)
6. Community care tops medical care at preventing heart disease in black Americans
7. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
8. Obesity among African-American stroke survivors increases risk factors for recurrent stroke
9. Awards & fellowships at the International & American Association for Dental Research General Session
10. American Academy of Neurology presents 57th Annual Meeting in Miami Beach
11. News tips from the 2005, 54th Annual Scientific Sessions of the American College of Cardiology

Post Your Comments:
(Date:4/18/2014)... (April 21, 2014) -- A group of scientists ... and the Sanders-Brown Center on Aging has found ... and neuropsychological function in Parkinson,s disease (PD). ... , the study, which assessed cognitive function in ... the dopamine replacement therapy commonly used to treat ...
(Date:4/18/2014)... memories? How did it make you feel? According to ... experience, such as how sad you were or how ... when you can,t stop thinking about it. , ... context of the memories, rather than how you felt, ... the negative effects of these memories, a new study ...
(Date:4/18/2014)... scientists could lead to potential new treatments for breaking ... , Fibrosis, or scarring, is a hallmark of ... lungs can lead to serious organ damage and, in ... options centers on findings made by Swati Bhattacharyya, PhD, ... that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
Cached News: